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Dominant congenital spinal muscular atrophy (DCSMA) is a disorder of developing anterior horn cells and shows lower-limb predom-
inance and clinical overlap with hereditary spastic paraplegia (HSP), a lower-limb-predominant disorder of corticospinal motor neurons.
We have identified fourmutations in bicaudal D homolog 2 (Drosophila) (BICD2) in six kindreds affected by DCSMA, DCSMAwith upper
motor neuron features, or HSP. BICD2 encodes BICD2, a key adaptor protein that interacts with the dynein-dynactin motor complex,
which facilitates trafficking of cellular cargos that are critical to motor neuron development and maintenance. We demonstrate that
mutations resulting in amino acid substitutions in two binding regions of BICD2 increase its binding affinity for the cytoplasmic
dynein-dynactin complex, which might result in the perturbation of BICD2-dynein-dynactin-mediated trafficking, and impair neurite
outgrowth. These findings provide insight into the mechanism underlying both the static and the slowly progressive clinical features
and the motor neuron pathology that characterize BICD2-associated diseases, and underscore the importance of the dynein-dynactin
transport pathway in the development and survival of both lower and upper motor neurons.Spinal muscular atrophies (SMAs) are a clinically and
genetically heterogeneous group of disorders affecting
motor neurons of the anterior horn of the spinal cord.
The most common form of SMA is caused by autosomal-
recessive mutations in survival of motor neuron 1 (SMN1
[MIM 600354]). Severe cases present in infancy with pro-
gressive weakness of proximal and axial muscles and early
death. In contrast, autosomal-dominant congenital SMA
(DCSMA) is characterized by nonprogressive congenital
or early-onset lower-limb-predominant weakness1–3 and
often results in significant mobility impairment. Heredi-
tary spastic paraplegia (HSP) is also a heterogeneous
predominantly lower-limb disorder that affects the upper
(corticospinal) motor neurons (UMNs). Onset is usually
in adulthood, and clinical features are progressive.4 Many
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The Amized, and the pathological mechanisms that underlie these
disorders have not been fully elucidated. Treatment is
essentially supportive, given that effective medical thera-
pies have not yet been developed.
We undertook a genome-wide Illumina SNP-based link-
age study by using DNA from four affected and five
unaffected family members from a large genetically un-
characterized DCSMA-affected kindred (AUS1, shown in
Figure 1) and identified six candidate linkage regions.5
Exome sequencing of genomic DNA from two affected
family members (III.2 and IV.5) was performed with the
Agilent SureSelect v.2 kit for capture and the Illumina
HiSeq 2000 sequencer. Reads were processed by Picard
and aligned to the human reference genome (UCSC
Genome Browser hg19)6 with the Burrows-Wheeler
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Figure 1. Pedigrees of Kindreds Affected by DCSMA, DCSMAþUMN, or HSP
A pattern consistent with autosomal-dominant inheritance is shown in five of the six kindreds. The sixth kindred, UK2, consists of a
simplex case, confirmed to be de novo by segregation analysis. Although there is no documented male-to-male transmission in
AUS1, linkage data had previously excluded X-linked loci in this kindred. The three pedigrees on the top row of the figure (AUS1,
AUSTRIA1, and USA1) share the same N-terminal p.Ser107Leu substitution; haplotype analysis suggests that AUS1 and AUSTRIA1 share
a common ancestry. USA1 also has European ancestry. The other three kindreds have kindred-specific mutations. The three c.320C>T
(p.Ser107Leu) kindreds are affected by a classical DCSMA phenotype, and limited UMN features are present only in USA1. Affected in-
dividuals in UK1 and UK2 have more marked UMN features. Germany 1 segregates with an HSP phenotype.small indels was performed with the Genome Analysis
Tool Kit.8 Variants were annotated with a modified version
of the Ensembl Variant Effect Predictor9 and filtered for in-
heritance patterns and predicted functional severity with
the xBrowse web server. xBrowse was used for identifying
variants that (1) were predicted to have a functional impact
on protein-coding regions (missense, nonsense, splice-dis-
rupting, or frameshift mutations) relative to the gene
models specified by Gencode v.12, (2) fell within regions
shown by previous linkage analysis to be identical by
descent in all affected individuals within the family, and
(3) had a frequency of less than 0.1% in data obtained
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project Exome Variant Server,
the 1000 Genomes Project, and over 1,000 internal-control
exome samples. xBrowse identified 162 rare (frequency <
1%) missense variants, in-frame insertions, deletions, and
predicted truncating variants shared by both affected fam-
ily members, but only the c.320C>T (p.Ser107Leu) variant
(RefSeq accession number NM_001003800.1) in bicaudal
D homolog 2 (Drosophila) (BICD2 [MIM 609797]), encod-
ing dynein-binding protein BICD2, was present in the pre-
viously identified linkage regions (max LOD ¼ 1.81).
Querying the Genome Variant Database for Human
Diseases (GVDHD) for additional novel (defined as absent966 The American Journal of Human Genetics 92, 965–973, June 6, 2from exome variant databases) BICD2 variants resulted in
the discovery of several UK- and Austria-based kindreds
and cases in which BICD2 had been recently identified as
a candidate gene for DCSMA. Whole-exome sequencing
of the index case of a second DCSMA-affected kindred,
showing additional UMN features (DCSMAþUMN) (UK1,
Figure 1), was performed, and the variants were filtered
as previously described.10,11 Of 96 filtered variants, the
c.1502G>C (p.Arg501Pro) variant in BICD2 was identified
as the likely causative mutation because the clinical
phenotype caused by its mutation is similar to that of
individuals with mutations in DYNC1H1 (MIM 600112),
encoding a known BICD2 binding partner, cytoplasmic
dynein 1 heavy chain 1.12
A genome-wide SNP (Affymetrix GeneChip Human
Mapping 10K array)-based multipoint linkage analysis
using genomic DNA from three affected and three unaf-
fected family members had been performed previously in
another DCSMA-affected kindred, AUSTRIA1 (Figure 1),
revealing ten linked loci, including the BICD2 locus on
chromosome 9. Subsequent whole-exome sequencing by
GVDHD resulted in the identification of a BICD2 variant
(c.320C>T [p.Ser107Leu]) as the likely causative mutation
in this kindred. Whole-exome sequencing of a simplex
DCSMAþUMN case (UK2, Figure 1) had been undertaken013














AUS1 DCSMA birth 6 c.320C>T p.Ser107Leu 0.999 39/40
AUSTRIA1 DCSMA birth 5 c.320C>T p.Ser107Leu 0.999 39/40
USA1 DCSMAþUMN birth 4 c.320C>T p.Ser107Leu 0.999 39/40
UK2 DCSMAþUMN birth 1 c.565A>T p.Ile189Phe 1.00 44/44
UK1 DCSMAþUMN birth 6 c.1502G>C p.Arg501Pro 0.98 34/44
GERMANY1 HSP adulthood 4 c.1523A>C p.Lys508Thr 0.912 32/44
In silico prediction of the functional consequences of the six mutations was performed with PolyPhen-2, and all six mutations were compared against the NHLBI
Exome Sequencing Project Exome Variant Server for confirmation of novelty.
aDCSMAþUMN indicates that UMN features were present in at least one family member.
bThe numerator indicates the number of species conserved for the unaltered amino acid at this location, and the denominator indicates the number of species for
which the amino acid sequence is known at this location (according to PolyPhen-2 data).within the UK10K Consortium. The identified variant
(c.565A>T [p.Ile189Phe]) was not present in either parent
(de novo dominant). Additional novel heterozygous
BICD2 variants with high in silico pathogenicity scores
were identified by GVDHD exome sequencing of DNA
from a further DCSMAþUMN-affected kindred (USA1
[c.320C>T (p.Ser107Leu)]) and a kindred affected by an
HSP phenotype (GERMANY1 [c.1523A>C (p.Lys508Thr)])
(Figure 1).
The six BICD2 mutations (summarized in Table 1) were
all confirmed by Sanger sequencing, and segregation
with the disease phenotype was confirmed in all family
members for whom DNA was available. The c.320C>T
(p.Ser107Leu) mutation is in a CpG dinucleotide and
thus most likely represents a methylcytosine-deamination
mutation. No additional novel heterozygous variants were
identified in 55 unrelated simplex and dominantly in-
herited UK and Australian DCSMA cases; however, addi-
tional novel variants have subsequently been identified
by the GVDHD team in other DCSMA, HSP, and DCSMAþ
UMN mixed-phenotype cases, and Sanger sequencing and
segregation confirmation are currently underway (S.Z., un-
published data).
Because the same mutation (c.320C>T [p.Ser107Leu]) is
present in AUS1 and AUSTRIA1, we analyzed the local
haplotype structure in a 200 kb window surrounding
BICD2 in AUS1 and AUSTRIA1 by using genotype data
from a genome-wide Illumina CytoSNP array. We deter-
mined that the mutation falls on a shared eight-SNP
haplotype with a background frequency in the European
population of approximately 2%, suggesting that the two
families share a relatively recent founder mutation.
USA1, which also segregates for c.320C>T (p.Ser107Leu),
has European ancestry and might also be related to AUS1
and AUSTRIA1.
The DCSMA-affected individuals presented with con-
genital or early-onset hip dislocation, lower-limb contrac-
tures, foot deformities, and predominantly distal leg
wasting (clinical images in Figure 2 and summary of clin-
ical features in Table 2). Weakness was often more markedThe Amproximally in the lower limbs; upper-limb involvement
wasmild. UMN signs, including brisk reflexes and extensor
plantar responses, were present in childhood in severely
affected individuals. Motor and sensory nerve conduction
studies were normal apart from reduced or absent peroneal
compound muscle action potentials representing second-
ary axonal loss in some individuals. Electromyography
(EMG) confirmed chronic denervation and reinnervation.
Lower-limb MRI demonstrated a consistent pattern of
muscle involvement (Figure 2) similar to that seen in indi-
viduals with DYNC1H1 mutations. The clinical features of
AUS1 have previously been reported.5 Postmortem find-
ings in an affected infant showed reduced numbers of
lumbar and, to a lesser extent, cervical anterior hornmotor
neurons, but there was no evidence of ongoing cell-
body or axonal degeneration.5 Members of GERMANY1,
affected by an HSP phenotype, did not develop features
until adulthood (20–70 years) (Table 1). As is typical for
this disorder, affected kindred members showed lower-
limb spasticity and hyperreflexia. Contractures, weakness,
and wasting were slowly progressive and less severe than
in DCSMA-affected kindreds. Because there is only one
family affected by pure UMN features, it is premature to
comment on genotype-phenotype correlations. This of
course will be of considerable interest as more families
are identified.
Bicaudal D (BICD), meaning ‘‘two tails,’’ was named
for the strikingly abnormal anterior-to-posterior body
patterning observed in BicD mutant Drosophila.13 The
BICD proteins (BicD in Drosophila and BICD1 and BICD2
in mammals) are adaptor proteins, which interact with
the dynein-dynactin motor complex and with the small
GTPase RAB614,15 to facilitate trafficking of key cellular car-
gos, including mRNA, Golgi, and secretory vesicles,14,16
all of which are critical to motor neuron development
and/or maintenance. During interphase, BICD2 has prop-
erties of a peripheral coat protein,15 which suggests a pref-
erence for membrane-bound cargos.
Human BICD2 contains five predicted coiled-coil bind-
ing domains grouped into three binding regions,15,17 aserican Journal of Human Genetics 92, 965–973, June 6, 2013 967
Figure 2. Clinical Features in Kindreds Affected by DCSMA Due to BICD2 Mutations
(A) A severely affected 4-year-old member of AUS1 (IV.5) shows marked wasting of the buttocks and entire lower limb, pes planus, and
calcaneovalgus foot deformities but preserved truncal and upper-limbmuscle bulk. This child has a wide-based waddling gait and hyper-
lordotic posture and uses a wheelchair to travel distances of more than a few hundred meters.
(B) AUS1 IV.5, now aged 7 years, shows stable wasting of the lower limbs and stable preservation of upper-limb muscle bulk. His sister
(IV.6) shares similar features. Both siblings have required noninvasive nocturnal ventilation since 4 years of age for obstructive sleep-
disordered breathing.
(C) MRI of the 32-year-old mother of siblings IV.5 and IV.6 shows a specific pattern of muscle involvement and sparing with or without
relative hypertrophy in the upper thigh and hallmark preservation of medial adductors and semitendinosus.
(D) TheMRI features of themother in (C) are identical to those of a 24-year-oldmale AUSTRIA1member, who shares the same c.320C>T
(p.Ser107Leu) mutation. Members of UK1 and UK2 have more severe muscle involvement, but sparing of the same subset of muscles
(e.g., medial adductors and semitendinosus in the upper thigh) is still evident. The lower-limbMRI features are almost identical to those
seen in individuals with DYNC1H1-associated DCSMA.shown in Figure 3A. The first N-terminal binding region
(CC1) interacts directly with cytoplasmic dynein,15 the
second (CC2) interacts with the kinesin motor complex
(kinesin-1: isoforms KIF5A and KIF5B),18 and the third
(CC3) interacts with RAB6.14 All four disease-causing pro-
tein alterations identified by this study lie within the first
two binding regions (Figure 3A).
In view of the known interaction between BICD2 and
the dynein-dynactin motor complex and the similarities
in clinical features between BICD2-associated DCSMA
and DYNC1H1-associated DCSMA,12 we sought to deter-
mine what effect two BICD2 variants (BICD2p.Ser107Leu in
CC1 and BICD2p.Arg501Pro in CC2) had on BICD2-dynein-
complex binding affinity. Full-length C-terminal Myc-
DDK-tagged human BICD2 cDNA in a p.CMV6 entry
plasmid (RC209960) was obtained from Origene Technol-
ogies. BICD2 mutations were introduced into the tran-
script by site-directed mutagenesis with a QuikChange II
XL kit (Stratagene) (primers are available upon request)
and were transfected into human embryonic kidney
(HEK) 293 cells with lipofectamine 2000 (Invitrogen)
according to themanufacturer’s instructions. For immuno-
precipitation, precleared cell lysate was incubated with
either anti-FLAG M2 affinity gel (Sigma) or dynein inter-968 The American Journal of Human Genetics 92, 965–973, June 6, 2mediate chain (DIC) antibody (a kind gift from K.K. Pfister,
University of Virginia) bound by Sepharose 4B protein A
beads (Invitrogen) on a shaker overnight at 4C. Proteins
were eluted into SDS-PAGE sample loading buffer and
loaded onto a NuPAGE 12% Bis-Tris gel (Invitrogen) for
immunoblot analysis.
HEK293 cells transfected with either wild-type or altered
Myc-DDK-tagged BICD2 demonstrated higher binding
affinity between BICD2 and DIC for both mutations (Fig-
ures 3B and 3C). Both altered BICD2 proteins also had
higher binding affinity for the p150Glued subunit of
dynactin (Figures 3B and 3D). Because the p.Ser107Leu
substitution lies within the dynein (CC1) binding region,
altered binding is likely to be a direct result of altered
BICD2-dynein interaction. Increased binding between
the dynein-dynactin complex and BICD2p.Arg501Pro might
be an indirect result of altered-BICD2-kinesin-1 binding,
which secondarily favors dynein binding.
In order to determine whether the increased affinity for
BICD2p.Ser107Leu and BICD2p.Arg501Pro with the dynein-
dynactin complex has any functional consequences
in vitro, we transfected SH-SY5Y cells with plasmids con-
taining the same two altered BICD2 constructs. In SH-
SY5Y cells, overexpressed wild-type BICD2 was diffusely013
Table 2. Clinical Features in Kindreds Affected by BICD2 Mutations
Kindred













Clinical phenotype DCSMA DCSMA DCSMAþUMNa DCSMAþUMNa DCSMAþUMNa HSP
Number of generations in pedigree 4 3 4 2 3 3
Number of affected and unaffected
individuals (clinically confirmed)
6 (4) 5 (3) 4 (4) 1 de novo (1) 5 (5) 4 (1)
Congenital and Early-Onset Contracture Dislocations
Congenital hip dysplasia and/or
joint dislocation
1 0 2 1 1 0
Congenital or early-onset hip
contracture
1 0 0 1 0 0
Congenital or early-onset knee
contracture
2 0 0 1 0 0
Congenital or early-onset
Achilles tendon contractures
2 2 0 1 5 0
Congenital talipes or early-onset
deformities
CV ¼ 4, EV ¼ 0 CV ¼ 2, EV ¼ 0 CV ¼ 0, EV ¼ 0 CV ¼ 1, EV ¼ 0 CV ¼ , EV ¼ 2 CV ¼ 0, EV ¼ 0
Foot Features and Abnormalities
High arch (H), pes cavus (C), or
pes planus (P)
H ¼ 0, C ¼ 0,
p ¼ 4
H ¼ 0, C ¼ 0,
p ¼ 0
H ¼ 0, C ¼ 3,
p ¼ 0
H ¼ 0, C ¼ 0,
p ¼ 0
H ¼ 1, C ¼ 0, 1
p ¼ 0
H ¼ 1, C ¼ 1,
p ¼ 0
Lower-Limb Features: Weakness and Wasting
Proximal ¼ distal weakness 3 3 2 1 2 1
Proximal > distal weakness 0 0 2 0 0 0
Distal > proximal weakness 1 0 0 0 2 0
Proximal ¼ distal wasting 3 3 2 0 3 0
Proximal > distal wasting 0 0 1 0 0 0
Distal > proximal wasting 1 0 1 1 1 1
No weakness or wasting but
other features (e.g., contractures)
0 0 0 0 1 0
Adult-onset lower-limb contractures,
weakness, and wasting
0 0 0 NA (child) 0 hip, Achilles
tendon
Lower-Limb Deep-Tendon Reflexes
Reduced or absent in lower limbs 4 2 (not tested
in the third)
1 1 1 0
Increased in lower limbs 0 0 0 0 2 1
Mixed (reduced and increased) in
lower limbs
0 0 2 0 2 0
Plantar Responses
Normal 4 2 (not tested
in the third)
4 0 3 0
Upgoing or equivocal 0 0 1 1 2 1
Upper-Limb Features: Weakness and Wasting









Mild wasting in one or more
regions
0 2 (shoulder, hand) 0 0 0 0
(Continued on next page)
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Table 2. Continued
Kindred
AUS1 AUSTRIA1 USA1 UK2 UK1 GERMANY1
No weakness or wasting 4 1 1 0 0 1
Adult-onset upper-limb contractures,
weakness, and wasting
0 0 0 NA (child) 0 0
Upper-Limb Deep-Tendon Reflexes
Reduced or absent in upper limbs 1 2 (not tested
in the third)
0 0 0 0
Increased in upper limbs 0 0 0 1 5 1
Mixed in upper limbs 0 0 0 0 0 0
Motor Development and Ambulation
Delayed early motor milestones 4 1 4 1 2 0
Wide-based gait and/or hyperlordotic
gait
2 2 1 1 1 0
High-stepping gait 0 3 0 0 0 0
Fatigues quickly when walking and
falls often
3 1 2 1 4 1
Uses orthoses and/or walking aide,
including frame
2 NA 3 0 0 1
Uses wheelchair 2 1 0 1 1 2
Respiratory Abnormalities
Obstructive sleep apnea symptoms
and/or signs and/or need for NiPV
3  1 0 0 
Restrictive lung disease and/or
reduced FVC
0  1 0 0 
Other Clinical Features
Vibration abnormality (V) and/or foot
paraesthesias (P)
0 0 3 (V: 1 with
diabetes)
0 0 1 (V and P)
Mild to moderate intellectual disability 1 0 0 0 1 0
Scoliosis (S), kyphosis (K), pectus
excavatum (P), bulbar weakness (B)
S ¼ 1, K ¼ 0,
p ¼ 1, B ¼ 1
S ¼ 1, K ¼ 0,
p ¼ 0, B ¼ 0
S ¼ 0, K ¼ 1,
p ¼ ?, B ¼ 0
S ¼ 0, K ¼ 0,
p ¼ 0, B ¼ 0
S ¼ 0, K ¼ 1,
p ¼ 0, B ¼ 0
S ¼ 0, K ¼ 0,
p ¼ 0, B ¼ 0
Surgery Required
Surgical relocation of one or both hip
and/or femoral osteotomies
1  0 1 1 0
Tendon-release surgery on foot and/or
other lower limb
1; 2 planned  0 1 3 0
Shown are the clinical features in six kindreds affected by DCSMA, HSP, or DCSMAþUMN due to BICD2 mutations. Abbreviations are as follows: CV,
calcaneovalgus; EV, equinovarus; NA, not available; NiPV, noninvasive pulmonary ventilation; and FVC, forced vital capacity.
aUMN signs present in lower limbs, upper limbs, or both in at least one affected kindred member.present throughout the cytoplasm (Figure 3E). In contrast,
in cells transfected with BICD2p.Arg501Pro, the altered
protein accumulated in the perinuclear region, where it
formed ring-like structures that colocalized with RAB6
(Figure 3E). These ring-like structures were not observed
in cells transfected with BICD2p.Ser107Leu (Figure 3E). For
BICD2p.Arg501Pro, it is possible that its higher affinity for
the dynein-dynactin complex results in increased seques-
tration of RAB6-positive vesicles to the pericentrosomal
region and decreased anterograde trafficking of secretory
vesicles to the plasma membrane.970 The American Journal of Human Genetics 92, 965–973, June 6, 2The bicaudal proteins play an important role in
neuronal development. In Drosophila, loss of BicD leads
to a congenital locomotor defect in larvae.19 During
neuronal differentiation, rapid outgrowth of neurite exten-
sions is dependent upon anterograde secretory traf-
ficking.20 BICD2 and a closely related member of the
BICD family, BICD-related protein 1 (BICDR-1), have
opposing dynein-dynactin-complex-dependent trafficking
roles that compete with one another to allow precise tem-
poral regulation of neurite outgrowth.17 During very early
neuronal development, BICDR-1 sequesters RAB6-positive013
Figure 3. Functional Characterization of BICD2 Mutations
(A) A schematic diagram demonstrating the three BICD2 regions composed of five coiled-coil domains, the four identified alterations,
and known interacting proteins.
(B) Coimmunoprecipitation studies of HEK293 cells transfected with BICD2 C terminally tagged with FLAG-Myc show a higher inter-
action between the p.Arg501Pro and p.Ser107Leu altered proteins and DIC and the p150Glued subunit of dynactin (band shownwith *).
The control represents a nontransfected cell lysate. For the FLAG-BICD2 pulldown, the pulled down DIC is highlighted by an arrow (the
upper band is present in the nontransfected control). Reverse immunoprecipitation with DIC antibody confirmed the increased inter-
action between the p.Arg501Pro and p.Ser107Leu variants and DIC.
(C and D) Optical densitometry for DIC and dynactin p150Glued pulldown for a single immunoprecipitation performed in triplicate.
ANOVA p ¼ 0.003 in (C), and ANOVA p ¼ 0.004 in (D). Error bars represent the SEM.
(E) Immunocytochemistry of SH-SY5Y cells transfected with constructs encoding p.Arg501Pro and p.Ser107Leu and stained for Myc and
RAB6 show the presence of a BICD2 p.Arg501Pro-RAB6 ring structure.secretory vesicles to a pericentrosomal location, which in-
hibits neurite outgrowth17 (Figure S1, available online). As
neurons mature, BICDR-1 expression falls, releasing RAB6-
positive secretory vesicles to the BICD2-adapted axonal-
transport pathways for anterograde trafficking to the
plasma membrane to facilitate neurite outgrowth.18,21
We propose that BICD2p.Ser107Leu and BICD2p.Arg501Pro per-
turb this process by favoring retrograde secretory-vesicle
trafficking away from the cell periphery and back toward
the pericentrosomal region (Figure S1). This would impair
embryonic development of motor neurons, a pathological
hallmark of DCSMA.13 Although DCSMA is primarily a
nonprogressive anterior horn cell disorder, features sugges-
tive of UMN loss become more prominent with age in
DCSMA and are a characteristic feature of HSP. This sug-
gests that mutations in BICD2 also have a detrimental
effect on the maintenance of a subpopulation of UMNs.
In conclusion, we have identified causative mutations
in BICD2, which encodes a dynein-dynactin traffickingThe Amadaptor protein, in six kindreds segregating for DCSMA,
DCSMAþUMN, or HSP. Mutations resulting in amino
acid substitutions in two binding regions increase bind-
ing affinity between BICD2 and the dynein-dynactin
complex, which is likely to result in altered specificity
and/or efficiency of key BICD2-mediated cellular traf-
ficking processes. We postulate that perturbation of
BICD2-mediated trafficking of RAB6-positive secretory
vesicles leads to impaired development and mainte-
nance of a key subset of anterior horn cells and UMNs
and thus results in both the static and the slowly
progressive features that characterize BICD2-associated
disorders.
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